Argenx Se, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a $915.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Douglas Tsao has given his Buy rating due to a combination of factors tied to Argenx’s strong commercial performance and emerging strategic opportunities. He underscores that the company has reached record revenue levels with rapid year-over-year and sequential growth, and has now crossed into operating profitability, supported by a rapidly expanding treated patient base and Vyvgart’s leading position among biologic therapies for myasthenia gravis. Physician feedback reinforcing Vyvgart’s preference and favorable reimbursement dynamics further strengthen the commercial outlook.
Tsao also highlights that near-term growth is underpinned by planned label expansions for Vyvgart into seronegative and ocular myasthenia gravis, with an over-enrolled pivotal ocular MG trial and encouraging real-world case reports increasing confidence in upcoming data. He notes additional upside from the company’s push into rheumatology indications such as myositis and Sjögren’s disease, where there is significant unmet need. Over the longer term, he points to a growing pipeline that includes next-generation FcRn programs like ARGX-213 and potentially best-in-class assets such as ARGX-117, as well as combination strategies in CIDP, as drivers of durable competitive advantage and value creation. Collectively, these elements support his view that Argenx can sustain strong growth and justify a Buy rating and elevated price target.